Sysmex (OTCMKTS:SSMXY) Shares Gap Down – Here’s Why

Sysmex Corporation ADR (OTCMKTS:SSMXY) gapped down prior to trading on Wednesday . The stock had previously closed at $10.02, but opened at $9.45. Sysmex shares last traded at $9.43, with a volume of 1,633 shares traded.

Analyst Ratings Changes

Separately, Zacks Research cut shares of Sysmex from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold”.

Sysmex Price Performance

The stock has a market cap of $5.96 billion, a P/E ratio of 24.93 and a beta of 1.07. The company has a current ratio of 3.26, a quick ratio of 2.46 and a debt-to-equity ratio of 0.12. The company’s fifty day simple moving average is $9.03 and its 200-day simple moving average is $9.07.

Sysmex (OTCMKTS:SSMXY) last announced its quarterly earnings data on Thursday, May 14th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The business had revenue of $877.92 million during the quarter, compared to analyst estimates of $862.45 million. Sysmex had a net margin of 7.13% and a return on equity of 7.23%. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. As a group, sell-side analysts forecast that Sysmex Corporation ADR will post 0.42 EPS for the current year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan?based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high?speed, high?volume testing for blood cell counts and differential analysis.